Axelia Oncology
1 known investors
Axelia Oncology develops cancer immunotherapies that activate the body's innate immune system, with a lead candidate, AXA-042, a systemically-delivered TLR2/6 agonist aimed at checkpoint-insensitive solid tumors. The company targets oncology indications where patients are resistant to checkpoint blockade therapy.
Investors · 1
In the news
Frequently asked questions
- What does Axelia Oncology do?
- Axelia Oncology develops cancer immunotherapies that activate the body's innate immune system, with a lead candidate, AXA-042, a systemically-delivered TLR2/6 agonist aimed at checkpoint-insensitive solid tumors. The company targets oncology indications where patients are resistant to checkpoint blockade therapy.
- Who are Axelia Oncology's investors?
- Axelia Oncology's investors include Stoic VC.